Robert J Bequette

US Patent:

44367384, Mar 13, 1984

Filed:

Mar 15, 1982

Appl. No.:

6/358068

Inventors:

Robert J. Bequette - Evansville IN
Linda G. Hobbs - Evansville IN
Joseph A. Scott - Evansville IN

Assignee:

Mead Johnson & Company - Evansville IN

International Classification:

A61K 3156

US Classification:

424238

Abstract:

Loss of potency of estradiol cream compositions found to be due to unexpected oxidation of estradiol. Improved cream composition comprises 1% or less 17. beta. -estradiol in the presence of stabilizing members selected from phenolic-type antioxidants, metal chelating agents, and suspending agents.

US Patent:

54550475, Oct 3, 1995

Filed:

Jun 15, 1994

Appl. No.:

8/259839

Inventors:

Robert J. Bequette - Evansville IN
Bruce A. Bonenberger - Evansville IN
Claude E. Gallian - Newburgh IN
John R. Reckelhoff - Evansville IN

Assignee:

Bristol-Myers Squibb Company - New York NY

International Classification:

A61K 932
A61K 942

US Classification:

424476

Abstract:

A directly compressed cholestyramine tablet with a solvent-free coating is disclosed. The inner core of the tablet is made up of cholestyramine agglomerates consisting of numerous small, irregularly-shaped, jagged-edged fragments having relatively few smooth or flat surfaces with a moisture content ranging from about 8 to 14 percent by weight. A process is also disclosed for preparing cholestyramine agglomerates of the invention. The solvent-free coating comprises from about 60 percent to about 95 percent by weight of stearic acid and from about 5 percent to about 40 percent of polyethylene glycol.

US Patent:

54139953, May 9, 1995

Filed:

Mar 8, 1985

Appl. No.:

6/709744

Inventors:

Robert L. Alexander - Evansville IN
Robert J. Bequette - Evansville IN
Terry T. Kensler - Evansville IN
Joseph A. Scott - Evansville IN

Assignee:

Mead Johnson & Company - Evansville IN

International Classification:

A61K 3166

US Classification:

514110

Abstract:

A lyophilized pharmaceutical solid composition containing cyclophosphamide for reconstitution with water to provide a solution for oral or parenteral administration. This lyophilized cyclophosphamide solid composition demonstrates improved stability, solubility characteristics and enhanced appearance compared with currently available dry powder pre-mix compositions of cyclophosphamide. The lyophilized solid composition contains about 20 parts by weight of cyclophosphamide, about 11/4-2 parts by weight of water and from about 10-85 parts by weight of excipient which is comprised mainly of mannitol. Processes for making the composition are disclosed.

US Patent:

53387325, Aug 16, 1994

Filed:

May 13, 1992

Appl. No.:

7/882218

Inventors:

Anne E. Atzinger - Lebanon IN
Robert J. Bequette - Evansville IN
Robert E. Davis - Evansville IN

Assignee:

Bristol-Myers Squibb Company - New York NY

International Classification:

A61K 3156

US Classification:

514178

Abstract:

The present invention relates to a novel oral pharmaceutical composition of micronized megestrol acetate at a concentration of 15 to 150 mg/mL comprising polysorbate at a concentration of 0. 005% to 0. 015% weight/volume and polyethylene glycol at a concentration of 5-30% weight/volume which composition forms a stable flocculated suspension in water. The invention further comprises the micronized megestrol acetate formulation described above with added preservatives, buffers, sweeteners and flavoring agents.

US Patent:

52273741, Jul 13, 1993

Filed:

Dec 23, 1991

Appl. No.:

7/812155

Inventors:

Robert L. Alexander - Evansville IN
Robert J. Bequette - Evansville IN
Terry T. Kensler - Evansville IN
Joseph A. Scott - Evansville IN

Assignee:

Mead Johnson & Company - Evansville IN

International Classification:

A61K 3166
A61K 3300

US Classification:

514110

Abstract:

A lyophilized pharmaceutical solid composition containing cyclophosphamide for reconstitution with water to provide a solution for oral or parenteral administration. This lyophilized cyclophosphamide solid composition demonstrates improved stability, solubility characteristics and enhanced appearance compared with currently available dry powder pre-mix compositions of cyclophosphamide. The lyophilized solid composition contains about 20 parts by weight of cyclophosphamide, about 11/4-2 parts by weight of water and from about 10-85 parts by weight of excipient which is comprised mainly of mannitol. Processes for making the composition are disclosed.

US Patent:

49561820, Sep 11, 1990

Filed:

Mar 16, 1989

Appl. No.:

7/324167

Inventors:

Robert J. Bequette - Evansville IN
Bruce A. Bonenberger - Evansville IN
Claude E. Gallian - Newburgh IN
John R. Reckelhoff - Evansville IN

Assignee:

Bristol-Myers Company - New York NY

International Classification:

A61K 942

US Classification:

424476

Abstract:

A directly compressed cholestyramine tablet with a solvent-free coating is disclosed. The inner core of the tablet is made up of cholestyramine agglomerates consisting of numerous small, irregularly-shaped, jagged-edged fragments having relatively few smooth or flat surfaces with a moisture content ranging from about 8 to 14 percent by weight. A process is also disclosed for preparing cholestyramine agglomerates of the invention. The solvent-free coating comprises from about 60 percent to about 95 percent by weight of stearic acid and from about 5 percent to about 40 percent of polyethylene glycol.

US Patent:

53728238, Dec 13, 1994

Filed:

Oct 22, 1992

Appl. No.:

7/965096

Inventors:

Robert J. Bequette - Evansville IN
Bruce A. Bonenberger - Evansville IN
Claude E. Gallian - Newburgh IN
John R. Reckelhoff - Evansville IN

Assignee:

Bristol-Myers Squibb Company - New York NY

International Classification:

A61K 920
A61K 916

US Classification:

424464

Abstract:

A directly compressed cholestyramine tablet with a solvent-free coating is disclosed. The inner core of the tablet is made up of cholestyramine agglomerates consisting of numerous small, irregularly-shaped, jagged-edged fragments having relatively few smooth or flat surfaces with a moisture content ranging from about 8 to 14 percent by weight. A process is also disclosed for preparing cholestyramine agglomerates of the invention. The solvent-free coating comprises from about 60 percent to about 95 percent by weight of stearic acid and from about 5 percent to about 40 percent of polyethylene glycol.

US Patent:

45378835, Aug 27, 1985

Filed:

Mar 13, 1984

Appl. No.:

6/589202

Inventors:

Robert L. Alexander - Evansville IN
Robert J. Bequette - Evansville IN
Terry T. Kensler - Evansville IN
Joseph A. Scott - Evansville IN

Assignee:

Mead Johnson & Company - Evansville IN

International Classification:

A61K 3166

US Classification:

514110

Abstract:

A lyophilized pharmaceutical solid composition containing cyclophosphamide for reconstitution with water to provide a solution for oral or parenteral administration. This lyophilized cyclophosphamide solid composition demonstrates improved stability, solubility characteristics and enhanced appearance compared with currently available dry powder pre-mix compositions of cyclophosphamide. The lyophilized solid composition contains about 20 parts by weight of cyclophosphamide, about 11/4-2 parts by weight of water and from about 10-85 parts by weight of excipient which is comprised mainly of mannitol. Processes for making the composition are disclosed.